These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 2780746)

  • 1. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac complications in homozygous beta-thalassemia.
    Wonke B; Hoffbrand AV; Aldouri MA; Ward SE
    Prog Clin Biol Res; 1989; 309():51-6. PubMed ID: 2780750
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical management of beta-thalassemia.
    Lerner N
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract]   [Full Text] [Related]  

  • 6. Measurement of iron status.
    Pippard MJ
    Prog Clin Biol Res; 1989; 309():85-92. PubMed ID: 2675108
    [No Abstract]   [Full Text] [Related]  

  • 7. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 9. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P; Forte L; Sorrentino F; Palombi M; Papa G; Marciani MG
    Bone Marrow Transplant; 1993; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C; Lagos P; Langona E
    Prog Clin Biol Res; 1979; 34():351-9. PubMed ID: 531060
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron chelation.
    Hershko C; Link G; Pinson A
    Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and economic burden of infused iron chelation therapy in the United States.
    Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
    Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy in sickle cell anemia.
    Cohen A; Schwartz E
    Am J Hematol; 1979; 7(1):69-76. PubMed ID: 507048
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral iron chelators.
    Nathan DG; Piomelli S
    Semin Hematol; 1990 Apr; 27(2):83-5. PubMed ID: 2190320
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatic iron stores in thalassemia: non-invasive magnetic measurements.
    Brittenham GM; Allen CJ; Farrell DE; Harris JW
    Prog Clin Biol Res; 1989; 309():101-6. PubMed ID: 2780744
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
    Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with therapy in Cooley's anaemia.
    Vullo C; Di Palma A
    Prog Clin Biol Res; 1989; 309():43-9. PubMed ID: 2780749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.